Niagen Bioscience Inc
OCD1
Company Profile
Business description
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Contact
10900 Wilshire Boulevard
Suite 600
Los AngelesCA90024
USAT: +1 310 388-6706
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
31 December 2026
Employees
117
Stocks News & Analysis
stocks
ASX payments utility looks overvalued
Australia’s invisible payments utility earns narrow moat yet valuation looks lofty.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,846.70 | 47.90 | -0.54% |
| CAC 40 | 7,769.21 | 95.86 | -1.22% |
| DAX 40 | 25,104.36 | 344.83 | -1.35% |
| Dow JONES (US) | 51,179.87 | 341.41 | -0.66% |
| FTSE 100 | 10,458.50 | 83.19 | -0.79% |
| HKSE | 24,130.50 | 150.06 | -0.62% |
| NASDAQ | 27,538.69 | 61.20 | -0.22% |
| Nikkei 225 | 69,256.84 | 778.87 | -1.11% |
| NZX 50 Index | 13,664.56 | 19.48 | -0.14% |
| S&P 500 | 7,801.77 | 17.16 | -0.22% |
| S&P/ASX 200 | 8,689.40 | 38.30 | -0.44% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |